Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

NCT04592874 is registered in ClinicalTrials.gov with Alector Inc. as lead sponsor.

NCT NCT04592874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04592874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Lead sponsor
Alector Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 22, 2021
Completion date
September 12, 2024
Enrollment
356 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease